Spicka, I. Et Al. 2021. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15 .

Spicka, I., Moreau, P., Martin, T. G., Facon, T., Martinez, G., Oriol, A., ... Koh, Y.(2021). Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

Spicka, Ivan Et Al. "Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Spicka, Ivan Et Al. "Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Spicka, I. Et Al. (2021) . "Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

@article{article, author={Ivan Spicka Et Al. }, title={Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}